Survey report: How today’s obesity developers are navigating a multi-indication landscape

From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. 

Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.

Survey results reveal widespread adoption of multi-indication development strategies across diverse disease indications, driven by compelling market forces and an improved understanding of disease MoAs. Most respondents believed that multi-indication drugs would ultimately reduce cost burdens on the health system.